PL2037962T3 - Sposób wprowadzania sirna do komórek drogą fotochemicznej internalizacji - Google Patents

Sposób wprowadzania sirna do komórek drogą fotochemicznej internalizacji

Info

Publication number
PL2037962T3
PL2037962T3 PL07733508T PL07733508T PL2037962T3 PL 2037962 T3 PL2037962 T3 PL 2037962T3 PL 07733508 T PL07733508 T PL 07733508T PL 07733508 T PL07733508 T PL 07733508T PL 2037962 T3 PL2037962 T3 PL 2037962T3
Authority
PL
Poland
Prior art keywords
sirn
entering
cells
photochemical internalization
internalization
Prior art date
Application number
PL07733508T
Other languages
English (en)
Inventor
Sigurd Bøe
Eivind Johannes Hovig
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of PL2037962T3 publication Critical patent/PL2037962T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PL07733508T 2006-07-11 2007-07-11 Sposób wprowadzania sirna do komórek drogą fotochemicznej internalizacji PL2037962T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0613753.3A GB0613753D0 (en) 2006-07-11 2006-07-11 Method
EP07733508.1A EP2037962B1 (en) 2006-07-11 2007-07-11 Method for introducing sirna into cells by photochemical internalisation
PCT/GB2007/002569 WO2008007073A2 (en) 2006-07-11 2007-07-11 Method for introducing sirna into cells by photochemical internalisation

Publications (1)

Publication Number Publication Date
PL2037962T3 true PL2037962T3 (pl) 2015-03-31

Family

ID=36955439

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07733508T PL2037962T3 (pl) 2006-07-11 2007-07-11 Sposób wprowadzania sirna do komórek drogą fotochemicznej internalizacji

Country Status (15)

Country Link
US (2) US20090297487A1 (pl)
EP (1) EP2037962B1 (pl)
JP (1) JP5269783B2 (pl)
CN (1) CN101573140B (pl)
AU (1) AU2007274056B2 (pl)
CA (1) CA2657999C (pl)
DK (1) DK2037962T3 (pl)
ES (1) ES2525222T3 (pl)
GB (1) GB0613753D0 (pl)
NO (1) NO342202B1 (pl)
NZ (1) NZ573775A (pl)
PL (1) PL2037962T3 (pl)
RU (1) RU2510826C2 (pl)
WO (1) WO2008007073A2 (pl)
ZA (1) ZA200810684B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
CA2708354C (en) * 2007-12-13 2018-12-11 Polyplus-Transfection Means for delivery of nucleic acids active for gene silencing using synthetic polymers
WO2009109862A2 (en) * 2008-03-06 2009-09-11 Rolf Lewensohn Improved cancer therapeutics
US20100056475A1 (en) * 2008-08-06 2010-03-04 Alexander Chucholowski Cyclodextrin conjugates
EP3214174B1 (en) 2010-03-04 2019-10-16 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
CN101831046B (zh) * 2010-03-30 2012-10-31 上海交通大学 交联剂和聚氨酯硬质泡沫材料及其制备方法
NZ605420A (en) 2010-07-06 2015-02-27 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
ES2886147T3 (es) 2011-12-22 2021-12-16 Interna Tech B V MiARN para el tratamiento del cáncer de cabeza y de cuello
US9907861B2 (en) 2012-01-18 2018-03-06 University Of Utah Research Foundation High molecular weight arginine-grafted bioreducible polymers
WO2014056590A1 (en) * 2012-10-08 2014-04-17 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
EP3019516B1 (en) 2013-07-12 2018-11-14 H. Hoffnabb-La Roche Ag Elucidation of ion exchange chromatography input optimization
AU2014314149B2 (en) * 2013-08-28 2019-12-19 Pci Biotech As Compound and method for vaccination and immunisation
EP3034539A1 (en) * 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
CN104878044B (zh) * 2015-04-29 2018-07-17 常州百代生物科技有限公司 一种脂类化合物siRNA转染试剂
WO2017191219A1 (en) * 2016-05-05 2017-11-09 Cosmophos Ltd Nano-systems for therapy and/or diagnosis and/or therapy monitoring and/or theranostics of disease
CN106924746B (zh) * 2017-03-03 2020-11-03 中山大学 复合基因载体及其应用
CN107011511B (zh) * 2017-06-01 2019-04-26 西南大学 一种原卟啉荧光碳点及制备方法和应用
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
EP3704250A1 (en) 2017-11-03 2020-09-09 InteRNA Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
GB201801169D0 (en) * 2018-01-24 2018-03-07 Pci Biotech As Method
WO2019222329A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2019241486A1 (en) 2018-06-13 2019-12-19 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
JP2021530548A (ja) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
JP2022512621A (ja) 2018-10-05 2022-02-07 ボイジャー セラピューティクス インコーポレイテッド Aav産生タンパク質をコードする操作された核酸コンストラクト
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3867389A1 (en) 2018-10-15 2021-08-25 Voyager Therapeutics, Inc. Expression vectors for large-scale production of raav in the baculovirus/sf9 system
MX2021008542A (es) 2019-01-18 2021-11-12 Voyager Therapeutics Inc Métodos y sistemas para la producción de partículas de aav.
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4301768A2 (en) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN114452406B (zh) * 2022-03-16 2023-05-23 安徽工程大学 一种抑菌材料及其制备方法和应用
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
AU2023417630A1 (en) 2022-12-29 2025-05-15 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
CN118207158B (zh) * 2023-06-21 2024-08-27 天津医科大学眼科医院 一种细胞内来源的纳米囊泡的制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
RU2066552C1 (ru) 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
FR2763943B1 (fr) * 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
HU229805B1 (en) 2000-11-29 2014-07-28 Pci Biotech As Photochemical internalization for delivery of molecules into the cytosol
EP1339862B1 (en) 2000-11-29 2014-01-08 PCI Biotech AS Photochemical internalization for virus-mediated molecule delivery into the cytosol
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Rna 간섭을 매개하는 작은 rna 분자
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
JP2006512906A (ja) * 2002-09-28 2006-04-20 マサチューセッツ インスティチュート オブ テクノロジー インフルエンザ治療剤
ATE465255T1 (de) * 2002-11-26 2010-05-15 Univ Massachusetts Verabreichung von sirnas
FR2858628B1 (fr) 2003-08-04 2008-01-04 Polyplus Transfection Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method

Also Published As

Publication number Publication date
EP2037962B1 (en) 2014-09-03
US20120264807A1 (en) 2012-10-18
AU2007274056B2 (en) 2013-08-01
NZ573775A (en) 2012-11-30
NO342202B1 (no) 2018-04-16
WO2008007073A3 (en) 2008-04-10
JP2010504080A (ja) 2010-02-12
CA2657999A1 (en) 2008-01-17
WO2008007073A2 (en) 2008-01-17
RU2510826C2 (ru) 2014-04-10
ZA200810684B (en) 2010-08-25
RU2008150847A (ru) 2010-06-27
CA2657999C (en) 2015-02-24
DK2037962T3 (en) 2014-12-15
AU2007274056A1 (en) 2008-01-17
CN101573140B (zh) 2014-04-23
NO20085259L (no) 2009-02-10
EP2037962A2 (en) 2009-03-25
GB0613753D0 (en) 2006-08-23
US9700622B2 (en) 2017-07-11
CN101573140A (zh) 2009-11-04
US20090297487A1 (en) 2009-12-03
JP5269783B2 (ja) 2013-08-21
ES2525222T3 (es) 2014-12-19

Similar Documents

Publication Publication Date Title
IL287311A (en) Antibodies and processes for preparing the same
PL2634243T3 (pl) Ulepszony sposób hodowli komórkowej
BRPI0919426A2 (pt) métodos melhorado de exposição de rna
BRPI0922440A2 (pt) dispositivo protético e método de fabricação do mesmo .
BRPI0909367A2 (pt) calçado e método de fabricação do mesmo
SI2358756T2 (sl) Visokoafinitetna humana protitelesa proti PCSK9
EP2285306A4 (en) ELECTROCAUTERIZATION PROCESS AND DEVICE
PT2371019T (pt) Acumulador de lítio e método de produção do mesmo
BRPI0917129A2 (pt) método de fabricação de fralda
DK2574677T3 (da) Fremgangsmåder til celledyrkning
EP2349097A4 (en) IMPROVED ARTIFICIAL HEARTLAP
EP2355757A4 (en) METHOD AND MEANS FOR ESTABLISHING REINFORCEMENT
EP2349095C0 (en) IMPROVED ARTIFICIAL HEART VALVE
EP2254597A4 (en) TREATMENT PROCEDURE WITH ANTI-MIF ANTIBODIES
ZA200810684B (en) Method for introducing sirna into cells by photochemical internalisation
BRPI0912799A2 (pt) fluxímetro, e, método
BR112012000735A2 (pt) "métodos, kits e conjuntos de compostos"
BRPI0919116A2 (pt) método
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BR112012004593A2 (pt) "método"
BRPI0823277A2 (pt) Composição, e , método
EP2207803A4 (en) Cd9-specific human antibodies
DK3135672T3 (da) Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme
DK2313489T3 (da) Fremstillingsmetode
BRPI0917684A2 (pt) método terapêutico homeopático